A COVID-19 vaccine developed in Edmonton is moving forward to human trials this summer.
The Government of Canada has granted Lewis $4.2 million to take the project to the next step, part of the Canadian Institutes of Health Research rapid research funding competition, which awarded $109 million to 139 research teams across the country this month.
The Entos vaccine is DNA-based. Unlike a traditional vaccine which gives patients an inactive virus to teach the body to fight the real thing, a genetic vaccine supplies a DNA blueprint for battle.
The Entos CEO said the method, named Fusogenix, has several advantages: stronger defence, a more stable vaccine and the ability to make a lot of product quickly.
“We’re working with a dose that can produce a very strong immune response, but will also allow us to scale up and manufacture sufficient doses for the Canada population.”
Entos will partner with the Canadian Center for Vaccinology and Dalhousie University in Nova Scotia for Phase 1 and 2 clinical trials.
“As we improve safety in those cohorts, we’ll move those into a Phase 2 setting, where we could use 600 to 800 patients.”
Phase 1 is expected to start in August in Halifax. Phase 2 could start in September, expanding across Canada and the U.S.
It is hoped Phase 3 can begin by the end of 2020. That portion would involve working with the World Health Organization to test the vaccine in regions of the world where there is active COVID-19 infection.
Lewis says his team is excited about the research, and Canadians seem enthusiastic too. There has been no shortage of volunteers.
“I think a lot of people are sitting at home and are frustrated that they can’t maybe do what they’re normally doing, so we’re seeing a lot of interest in participating in the trial.”